Study S002396

The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06528405
Acronym: ESS-AKD
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: RECRUITING
Enrollment: 264
Start: 2024-11-21
Primary completion: 2027-07
Lead sponsor: National Taiwan University Hospital
Conditions: Acute Kidney Injury
Interventions: DRUG:dapagliflozin; OTHER:Other anti-diabetic drug or no anti-diabetic drug; DRUG:empagliflozin; DRUG:canagliflozin
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Albuminuria [Day 28 and Day 90]
Discontinuation of SGLT2i [Day 0 to Day 90]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.